# Amy Cha

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/amy-cha/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,683 |
| Field | Dermatology and Skin Diseases |
| h-index | 18 |
| i10-index | 28 |
| Last Known Institution | Pfizer (United States) |
| OpenAlex ID | https://openalex.org/A5030937777 |
| ORCID iD | 0000-0002-1243-9112 |
| Works | 69 |

## Researcher papers

- [Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, 2020](https://scholariq.org/papers/health-insurance-coverage-early-release-of-estimates-from-the-national-health/)
- [Association Between Social Vulnerability and a County’s Risk for Becoming a COVID-19 Hotspot — United States, June 1–July 25, 2020](https://scholariq.org/papers/association-between-social-vulnerability-and-a-county-s-risk-for-becoming-a/)
- [In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo.](https://scholariq.org/papers/in-vitro-and-in-vivo-activity-of-protein-kinase-c-inhibitor-chelerythrine/)
- [Health insurance coverage: Early release of estimates from the National Health Interview Survey, January–June 2021](https://scholariq.org/papers/health-insurance-coverage-early-release-of-estimates-from-the-national-health-2/)
- [Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting](https://scholariq.org/papers/recent-developments-and-advances-in-atopic-dermatitis-a-focus-on-epidemiology/)
- [Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)](https://scholariq.org/papers/safety-effectiveness-and-pharmacokinetics-of-crisaborole-in-infants-aged-3-to/)
- [Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management](https://scholariq.org/papers/stasis-dermatitis-an-overview-of-its-clinical-presentation-pathogenesis-and/)
- [Vehicles for atopic dermatitis therapies: more than just a placebo](https://scholariq.org/papers/vehicles-for-atopic-dermatitis-therapies-more-than-just-a-placebo/)
- [Demographic Variation in Health Insurance Coverage: United States, 2020](https://scholariq.org/papers/demographic-variation-in-health-insurance-coverage-united-states-2020/)
- [Similarities and differences in peripheral itch and pain pathways in atopic dermatitis](https://scholariq.org/papers/similarities-and-differences-in-peripheral-itch-and-pain-pathways-in-atopic/)
- [Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey](https://scholariq.org/papers/clinical-and-humanistic-burden-of-atopic-dermatitis-in-europe-analyses-of-the/)
- [Care pathways in atopic dermatitis: a retrospective <scp>population‐based</scp> cohort study](https://scholariq.org/papers/care-pathways-in-atopic-dermatitis-a-retrospective-scp-population-based-scp/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Healthcare Policy and Management](https://scholariq.org/topics/healthcare-policy-and-management/)

## Researcher university

- [Pfizer (United States)](https://scholariq.org/institutions/pfizer-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.